IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Raised by NEOS Investment Management LLC

NEOS Investment Management LLC lifted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 10.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 16,066 shares of the company’s stock after buying an additional 1,577 shares during the quarter. NEOS Investment Management LLC’s holdings in IDEAYA Biosciences were worth $413,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Rhumbline Advisers increased its stake in IDEAYA Biosciences by 0.5% during the fourth quarter. Rhumbline Advisers now owns 113,561 shares of the company’s stock valued at $2,919,000 after purchasing an additional 585 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock valued at $72,000 after buying an additional 853 shares during the period. Assetmark Inc. grew its position in shares of IDEAYA Biosciences by 2.5% during the 4th quarter. Assetmark Inc. now owns 45,269 shares of the company’s stock valued at $1,163,000 after buying an additional 1,084 shares during the last quarter. R Squared Ltd acquired a new stake in IDEAYA Biosciences during the fourth quarter worth about $35,000. Finally, Bellevue Group AG lifted its holdings in IDEAYA Biosciences by 26.3% in the third quarter. Bellevue Group AG now owns 7,200 shares of the company’s stock worth $228,000 after acquiring an additional 1,500 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Price Performance

NASDAQ IDYA opened at $16.38 on Tuesday. IDEAYA Biosciences, Inc. has a 12 month low of $15.94 and a 12 month high of $44.42. The firm has a market capitalization of $1.43 billion, a PE ratio of -4.96 and a beta of 0.76. The company’s 50 day simple moving average is $20.68 and its 200 day simple moving average is $25.63.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Thursday, February 13th. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.82). The firm had revenue of $7.00 million during the quarter, compared to the consensus estimate of $7.00 million. Sell-side analysts anticipate that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on IDYA shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Wedbush restated an “outperform” rating and set a $52.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Stephens reiterated an “overweight” rating and issued a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $53.58.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.